Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
Recruiting · NCT06670222 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) | Low-risk Myelodysplastic Syndromes | Recruiting | Phase 1 | 2026-09-10 | NCT06670222 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Groupe Francophone des Myelodysplasies | 10 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CHU de Nice - Hôpital l'Archet - Service d'hématologie clinique | Nice | France | 1 |
| Hôpital Saint Louis - Service Hématologie séniors | Paris | France | 2 |
| Institut Gustave Roussy - Service d'hématologie | Villejuif | France | 1 |